Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122907683 | 12290768 | 3 | F | 20160726 | 20160421 | 20160802 | PER | US-PFIZER INC-2016219800 | PFIZER | 29.00 | YR | M | Y | 0.00000 | 20160802 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122907683 | 12290768 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | 150 MG, DAILY | Y | 20699 | 150 | MG | PROLONGED-RELEASE CAPSULE | |||||||
122907683 | 12290768 | 2 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | 75 MG, 2X/DAY | Y | 20699 | 75 | MG | PROLONGED-RELEASE CAPSULE | BID | ||||||
122907683 | 12290768 | 3 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Y | 20699 | PROLONGED-RELEASE CAPSULE | ||||||||||
122907683 | 12290768 | 4 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
122907683 | 12290768 | 1 | Obsessive-compulsive disorder |
122907683 | 12290768 | 2 | Anxiety |
122907683 | 12290768 | 3 | Depression |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
122907683 | 12290768 | Abdominal discomfort | |
122907683 | 12290768 | Drug effect incomplete | |
122907683 | 12290768 | Drug intolerance |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |